Insider Buys Big on Beaten-Down Biotech Stocks | Nuvation Bio & Ardelyx

Insiders at Nuvation Bio and Ardelyx are showing confidence in their companies despite struggling stock prices. Nuvation CEO David Hung recently made a $893,500 purchase of 500,000 shares, while Ardelyx Chairman David Mott invested $1.46 million for 400,000 shares. Both stocks are down sharply in 2023, but these big insider buys could signal a potential turnaround. Are these biotech stocks a buy now?

Keywords:
Insider buys, Nuvation Bio, Ardelyx, biotech stocks, David Hung, David Mott, insider trading, biotech investment, stock market, biotechnology news, biotech downturn, Nuvation stock, Ardelyx stock, SEC filings, biotech insider purchases, stock analysis, investment trends.

Hashtags:
#InsiderBuys #NuvationBio #Ardelyx #BiotechStocks #StockMarket #DavidHung #DavidMott #BiotechInvesting #StockAnalysis #BiotechNews #InvestmentTrends

Видео Insider Buys Big on Beaten-Down Biotech Stocks | Nuvation Bio & Ardelyx канала SnapShot Sphere